Abstract:KCNQ5 encodes the voltage-gated potassium channel K V 7.5, a member of the K V 7 channel family, which conducts the M-current. This current is a potent regulator of neuronal excitability by regulating membrane potential in the subthreshold range of action potentials and mediating the medium and slow afterhyperpolarization. Recently, we have identified five loss-of-function variants in KCNQ5 in patients with genetic generalized epilepsy. Using the most severe dominant-negative variant (R359C), we set out to investigate pharmacological therapeutic intervention by K V 7 channel openers on channel function and neuronal firing. Retigabine and gabapentin increased R359C-derived M-current amplitudes in HEK cells expressing homomeric or heteromeric mutant K V 7.5 channels. Retigabine was most effective in restoring K + currents. Ten μM retigabine was sufficient to reach the level of WT currents without retigabine, whereas 100 μM of gabapentin showed less than half of this effect and application of 50 μM ZnCl 2 only significantly increased M-current amplitude in heteromeric channels. Overexpression of K V 7.5-WT potently inhibited neuronal firing by increasing the M-current, whereas R359C overexpression had the opposite effect and additionally decreased the medium afterhyperpolarization current. Both aforementioned drugs and Zn 2+ reversed the effect of R359C expression by reducing firing to nearly normal levels at high current injections. Our study shows that a dominant-negative variant with a complete loss-of-function in K V 7.5 leads to largely increased neuronal firing which may explain a neuronal hyperexcitability in patients. K V 7 channel openers, such as retigabine or gabapentin, could be treatment options for patients currently displaying pharmacoresistant epilepsy and carrying loss-of-function variants in KCNQ5 .

Four drug-sensitive subunits are required for maximal effect of a voltage sensor–targeted KCNQ opener

Pore- and voltage sensor–targeted KCNQ openers have distinct state-dependent actions

Isoform-specific Prolongation of Kv7 (KCNQ) Potassium Channel Opening Mediated by New Molecular Determinants for Drug-Channel Interactions

The Tetramerization Domain Potentiates Kv4 Channel Function by Suppressing Closed-State Inactivation.

A-Type Kv4 Channel Closed-State Inactivation is Modulated by the Tetramerization Domain Interacting with Auxilary KChIP4a

Structural Basis for the Modulation of Human KCNQ4 by Small-Molecule Drugs

Molecular Basis for Ligand Activation of the Human KCNQ2 Channel.

Retigabine and gabapentin restore channel function and neuronal firing in a cellular model of an epilepsy-associated dominant-negative KCNQ5 variant

A Small-Molecule Activation Mechanism That Directly Opens the KCNQ2 Channel

Structural Mechanisms for the Activation of Human Cardiac KCNQ1 Channel by Electro-Mechanical Coupling Enhancers

An Activator Binding Site in the Gating Charge Pathway of KCNQ2 Channel

Pharmacological Activation of Normal and Arrhythmia-Associated Mutant KCNQ1 Potassium Channels

A Kv2 inhibitor combination reveals native neuronal conductances consistent with Kv2/KvS heteromers

Differential Modulations of KCNQ1 by Auxiliary Proteins KCNE1 and KCNE2

Building KCNQ1/KCNE1 Channel Models and Probing Their Interactions by Molecular-Dynamics Simulations.

The Gating Charge Pathway of an Epilepsy-Associated Potassium Channel Accommodates Chemical Ligands

Functional characterization and in vitro pharmacological rescue of KCNQ2 pore mutations associated with epileptic encephalopathy

Effect of two activators on the gating of a K channel

ML277 specifically enhances the fully activated open state of KCNQ1 by modulating VSD-pore coupling

Intersubunit Concerted Cooperative and Cis-Type Mechanisms Modulate Allosteric Gating in Two-Pore-Domain Potassium Channel TREK-2.

A new twist to increase ion flow